Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 14

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
    Outstanding as of September 30, 2025 
     104,396  
    $125.59  
     7.0  
    $- 
  
    Exercisable as of September 30, 2025 
     78,341  
    $155.99  
     6.4  
    $- 
  
    Vested and expected to vest as of September 30, 2025 
     104,396  
    $125.59  
     7.0  
    $- 

The
following table summarizes the total stock-based compensation expense included in the unaudited condensed consolidated statements of
operations for the periods presented:

 SCHEDULE OF STOCK BASED COMPENSATION EXPENSES 

    2025  
    2024  
    2025  
    2024 

    For the three months ended
                                                                               September 30,  
    For the nine months ended
                                                                               September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Research and development 
    $61,872  
    $108,447  
    $191,401  
    $547,927 
  
    General and administrative 
     88,742  
     335,737  
     380,867  
     1,453,800 
  
    Total stock-based compensation expense 
    $150,614  
    $444,184  
    $572,268  
    $2,001,727 

As
of September 30, 2025, total compensation cost not yet recognized related to unvested stock options was approximately $0.45 million,
which is expected to be recognized over a weighted-average period of approximately 1.0 years.

The
Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes
option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted
average inputs used to measure the value of the options granted during the nine months ended September 30, 2025, are presented in the
table below. The weighted average fair value of stock options granted during the nine months ended September 30, 2025 was $8.14 per share